ArticlePloS one2025
Integrating bioactivity and molecular simulations to explore the pharmacological landscape of Lagerstroemia speciosa leaf extract.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioactive Fractions fromMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural resources are vital for identifying novel treatments for noncommunicable diseases and multidrug-resistant pathogens. Lagerstroemia speciosa (L. speciosa) Linn. is traditionally used to manage conditions like diabetes, cancer, and oxidative stress-related diseases. Current studies frequently lack comprehensive bioactivity assessments coupled with molecular simulation analyses of L. speciosa leaf extracts. We aimed to assess the phytochemical profiling, bioactivity, in silico pharmacological properties, and molecular interactions of L. speciosa leaf extracts prepared using organic solvents. Methanol (5.1) and ethanol (4.3) extracts yielded the highest concentrations of total phenolics, flavonoids, and proanthocyanidins due to their high polarity indices. Antioxidant activities were robustly evaluated using DPPH, ABTS, superoxide, and nitric oxide assays, with the ethanol extract demonstrating significant free radical scavenging (IC50 = 75.53 µg/mL for DPPH). The methanol extract exhibited broad-spectrum antibacterial activity against multidrug-resistant strains, including Escherichia coli and Staphylococcus aureus, alongside moderate antifungal activity against Candida albicans and Saccharomyces cerevisiae. The brine shrimp lethality assay revealed moderate cytotoxicity (LC50 = 601.8 µg/mL), suggesting potential anticancer properties likely mediated by bioactive compounds such as ellagic acid and gallic acid. Methanol and ethanol extracts of L. speciosa significantly inhibited α-amylase and α-glucosidase compared to standard acarbose, indicating substantial antidiabetic potential by delaying carbohydrate digestion and reducing postprandial glucose levels. Complementary molecular docking and ADME pharmacokinetic studies provided in silico support for the observed antioxidant, antimicrobial, antidiabetic, and chemopreventive activities. The compelling evidence collectively suggests that L. speciosa extracts are a promising source of bioactive compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.